Centenial Surgical Suture Ltd vs Sharma East India Hosp And Medical Research Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Centenial Surgical Suture Ltd is ₹ 67.95 as of 23 Oct 15:30 . The P/E Ratio of Centenial Surgical Suture Ltd changed from 24.1 on March 2021 to 0 on March 2026 . This represents a CAGR of -100.00% over 6 yearsThe P/E Ratio of Sharma East India Hosp and Medical Research Ltd changed from 24.9 on March 2025 to 34.6 on March 2026 . This represents a CAGR of 17.88% over 2 years The Market Cap of Centenial Surgical Suture Ltd changed from ₹ 15.6 crore on March 2021 to ₹ 27.83 crore on March 2026 . This represents a CAGR of 10.13% over 6 yearsThe Market Cap of Sharma East India Hosp and Medical Research Ltd changed from ₹ 24.42 crore on March 2025 to ₹ 33.94 crore on March 2026 . This represents a CAGR of 17.89% over 2 years The revenue of Centenial Surgical Suture Ltd for the Jun '26 is ₹ 15.35 crore as compare to the Mar '26 revenue of ₹ 12.65 crore. This represent the growth of 21.34% The revenue of Sharma East India Hosp and Medical Research Ltd for the Jun '26 is ₹ 10.8 crore as compare to the Mar '26 revenue of ₹ 7.49 crore. This represent the growth of 44.19% The ebitda of Centenial Surgical Suture Ltd for the Jun '26 is ₹ 2.19 crore as compare to the Mar '26 ebitda of ₹ 1 crore. This represent the growth of 119% The ebitda of Sharma East India Hosp and Medical Research Ltd for the Jun '26 is ₹ 0.9 crore as compare to the Mar '26 ebitda of ₹ 1.03 crore. This represent the decline of -12.62% The net profit of Centenial Surgical Suture Ltd changed from ₹ 0.3 crore to ₹ 0.74 crore over 9 quarters. This represents a CAGR of 49.37% The net profit of Sharma East India Hosp and Medical Research Ltd changed from ₹ 0.25 crore to ₹ 0.26 crore over 9 quarters. This represents a CAGR of 1.76% The Dividend Payout of Centenial Surgical Suture Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Sharma East India Hosp and Medical Research Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Centenial Surgical Suture Ltd

Incorporated in 1995, Centenial Surgical Suture Limited is engaged in the manufacture and sale of surgical sutures in India.
The company offers absorbable sutures that include natural and synthetic sutures and non absorbable sutures comprising needles for cardiovascular surgery, monofilament polyamide atraumatic needle suture combinations, monofilament stainless steel, and temporary pacemaker electrodes.
It also provides female urinary incontinency sets, titanium haemostatic clips for cardiovascular surgery, non absorbable. Company leverages the expertise and application knowledge of the global suture requirements for cardiovascular sutures in particular, to bring advanced atraumatic needle product development to the Indian Surgeons.
Continuous innovation in the areas of design, research and development of atraumatic needle, simulation and validation, testing and services, are the key value creation driver for the Company.

About Sharma East India Hosp and Medical Research Ltd

Sharma East India Hospitals & Medical Research Limited was incorporated on November 16, 1989.
The Company is engaged in providing medical and healthcare services and real estate services and is presently running a multi-specialty hospital in the name of 'Jaipur Hospital' at Lal Kothi, at Rajasthan since 1989. As far as the achievements of the Company are concerned, the first assessment of the Company was conducted by National Accreditation Board for Hospitals and Health Care Providers (NABH), NABH accreditation system is one of the methods for commitment to quality enhancement throughout whole of the health care system in India.
It involves all professional and service groups to ensure that high quality in health care is achieved, while minimizing the inherent risks associated with modern health care delivery.

FAQs for the comparison of Centenial Surgical Suture Ltd and Sharma East India Hosp and Medical Research Ltd

Which company has a larger market capitalization, Centenial Surgical Suture Ltd or Sharma East India Hosp and Medical Research Ltd?

Market cap of Centenial Surgical Suture Ltd is 24 Cr while Market cap of Sharma East India Hosp and Medical Research Ltd is 25 Cr

What are the key factors driving the stock performance of Centenial Surgical Suture Ltd and Sharma East India Hosp and Medical Research Ltd?

The stock performance of Centenial Surgical Suture Ltd and Sharma East India Hosp and Medical Research Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Centenial Surgical Suture Ltd and Sharma East India Hosp and Medical Research Ltd?

As of October 25, 2026, the Centenial Surgical Suture Ltd stock price is INR ₹67.95. On the other hand, Sharma East India Hosp and Medical Research Ltd stock price is INR ₹79.15.

How do dividend payouts of Centenial Surgical Suture Ltd and Sharma East India Hosp and Medical Research Ltd compare?

To compare the dividend payouts of Centenial Surgical Suture Ltd and Sharma East India Hosp and Medical Research Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.